--- a
+++ b/clusters/9knumclustersv2/clust_1174.txt
@@ -0,0 +1,65 @@
+Part C: Patients must have measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI)
+Patients must have a diagnostic quality computed tomography (CT) scan or magnetic resonance imaging (MRI), performed within  days prior to registration, which demonstrates measurable disease, as defined in RECIST v. .; all disease must be assessed and documented on the S Baseline Tumor Assessment Form
+In the expansion cohort: subjects must have at least one lesion that is not within a previously radiated field that is measurable on computerized tomography (CT) or magnetic resonance imaging (MRI) scan per RECIST version .; bone lesions are not considered measurable by definition
+At least one measurable lesion by computed tomography (CT) scan or magnetic resonance imaging (MRI) based on RECIST version .
+At least  measurable lesion as defined by RECIST . on imaging studies (computed tomography [CT] or magnetic resonance imaging [MRI])
+All patients must have measurable disease documented by computed tomography (CT), magnetic resonance imaging (MRI), or nonmeasurable disease documented by physical exam within  days prior to registration
+Patients must have measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) scan per RECIST v..
+Patients must have measurable or non-measurable (evaluable) disease recurrence; recurrence must be documented by magnetic resonance imaging (MRI) or computed tomography (CT) scan
+Patients must have measurable disease according to RECIST criteria on anatomic imaging studies (computed tomography [CT] scan or magnetic resonance imaging [MRI])
+Measurable disease on imaging studies (magnetic resonance imaging [MRI], computed tomography [CT], PET-CT or physical exam)
+Subject has at least  measurable lesion per RECIST v. criteria by computed tomography (CT) scan or magnetic resonance image (MRI).
+Patient must have recent imaging (computed tomography [CT] or magnetic resonance imaging [MRI], as appropriate) within  weeks of trial enrollment, demonstrating measurable disease as defined by RECIST ..
+Evaluable disease by clinical exam (i.e., palpable lymphadenopathy, measurable skin lesions, etc.), laboratory assessment (i.e., lymphoma involvement of bone marrow or peripheral blood by morphology, cytology or flow cytometry), and/or imaging (measurable lymph nodes or masses on computed tomography (CT) or magnetic resonance imaging (MRI) and/or evaluable FDG-avid lesions on PET)
+Measurable disease, even after resection of applicable lesion for TIL harvest; defined as >=  lesion that is >=  mm in one dimension by computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers on clinical exam
+Measurable disease by RECIST v. criteria (tumor >=  cm in longest diameter on axial image on computed tomography (CT) or magnetic resonance imaging (MRI) and/or lymph node(s) >= . cm in short axis on CT or magnetic resonance imaging [MRI]) on baseline imaging
+Patients must have at least one lesion that is not within a previously radiated field and that is measurable on computerized tomography (CT) or magnetic resonance imaging (MRI) scans per RECIST version .; bone lesions are not considered measurable
+Active disease measurable by computed tomography (CT) or magnetic resonance imaging (MRI)
+Patients must have measurable disease according to the standard RECIST version .\r\n* NOTE: computed tomography (CT) scans or magnetic resonance imaging (MRI)s used to assess the measurable disease must have been completed with  days prior to the study drug initiation
+At least  measurable lesion > . cm in at least  dimension by computed tomography or magnetic resonance imaging.
+Measurable disease at baseline as assessed by computed tomography (CT) and/or magnetic resonance imaging (MRI)
+At least one measurable lesion that can be accurately assessed at baseline by computed tomography (CT) (or magnetic resonance imaging [MRI] suitable for assessment as per RECIST .. The baseline scan must be obtained within  days prior to the first dose of olaparib.
+Patients must have measurable disease, by computed tomography (CT) or magnetic resonance imaging (MRI) per modified RECIST criteria for mesothelioma; radiographic tumor assessment must be performed within  days prior to the first treatment
+Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) as defined by RECIST .
+Must have evaluable disease by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan, according to RECIST . (subjects with measurable disease per RECIST . or radiographically visible and evaluable disease). Subjects with only ascites or pleural effusion are excluded.
+Participants must have evaluable or measurable disease based on RECIST . using computed tomography (CT)/magnetic resonance imaging (MRI).
+Measurable disease by computed tomography (CT) or similar (e.g. magnetic resonance imaging [MRI]) criteria (> . cm)
+Disease in the liver must be measurable by computed tomography (CT) and/or magnetic resonance imaging (MRI).
+Measurable disease by computed tomography or magnetic resonance imaging based on RECIST . as determined by site radiology.
+Patients must have measurable disease per RECIST . assessed by computed tomography (CT) scan or magnetic resonance imaging (MRI)
+At least  radiographically measureable lesion by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST . criteria. Target lesions may be located in a previously irradiated field if there is documented (radiographic) disease progression in that site
+Must have measurable disease per RECIST . as assessed by computed tomography (CT) scan or magnetic resonance imaging (MRI). a. Lesion/s deemed accessible to biopsy for both before and on-treatment biopsies.
+Measurable or evaluable disease on computed tomography (CT) or magnetic resonance imaging (MRI) scan per RECIST version (v).
+Must have measurable disease by computed tomography (CT) scan or magnetic resonance imaging (MRI)
+Patients will only be eligible for this trial if they have disease with tumor measurable on the computed tomography (CT) scan or magnetic resonance imaging (MRI)
+Patients must have at least one measurable lesion at baseline by computed tomography (CT) or magnetic resonance imaging (MRI) as per RECIST v. criteria.
+Measurable Diffuse Large B-Cell Lymphoma disease by Computed Tomography (CT) / Magnetic Resonance Imagining (MRI) scans
+Patients must have measurable disease in the pancreas; computed tomography (CT) scans or magnetic resonance imaging (MRIs) used to assess measurable disease must have been completed within  days prior to registration; all disease must be assessed and documented on the baseline tumor assessment form
+Measurable disease determined by computed tomography (CT) or magnetic resonance imaging (MRI)
+Presence of at least  measurable lesion by computed tomography or magnetic resonance imaging per RECIST v..
+Measurable disease defined per RECIST v. ., or bone-only disease must have a lytic or mixed lytic blastic lesion that can be accurately assessed by computed tomography (CT) or magnetic resonance imaging (MRI). Individuals with bone-only disease and blastic-only metastases are not eligible
+Has progression and measurable disease in the brain by magnetic resonance imaging (MRI) or computed tomography (CT)
+Measurable disease at baseline as assessed by computed tomography (CT) and/or magnetic resonance imaging (MRI)
+Bi-dimensionally measurable disease on cross sectional imaging by X-ray Computed Tomography (CT) or Magnetic Resonance Imaging (MRI).
+Subjects must have measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST . criteria; radiographic tumor assessment performed within  days of study inclusion
+Metastatic diseases measurable or evaluable on a computed tomography (CT) or magnetic resonance imaging (MRI) scan according to RECIST . criteria; locally recurrent disease that is not amenable to potentially curative surgery or radiation therapy is also allowed; lesions must be >=  mm in size; recurrent or metastatic disease within a prior radiation field is acceptable as long as the disease has progressed in the radiation field by RECIST criteria
+Subject has measurable disease by radiographic techniques (computerized tomography [CT] or magnetic resonance imaging [MRI]);
+Measurable disease by computed tomography (CT) or Magnetic Resonance Imaging (MRI) per RECIST . criteria
+one site of measurable disease by magnetic resonance imaging (MRI) or computed tomography (CT) scan defined as at least one lesion that measures at least .  . cm, Exception: For patients with MCL only, patients with nonmeasurable disease but evaluable sites (bone marrow, spleen, peripheral blood, gastrointestinal tract) can be enrolled.
+Measurable disease by Computed tomography (CT)/Magnetic resonance imaging (MRI) per RECIST . criteria
+Has progression of brain cancer and measurable disease by magnetic resonance imaging (MRI) or computed tomography (CT) scan; for leptomeningeal metastases, positive cytology is acceptable if imaging is not measurable
+At least  lesion (measurable by RECIST v.) that can be accurately assessed at baseline by computed tomography (CT)/magnetic resonance imaging (MRI) and is suitable for repeated assessment;
+Subjects must have evidence of measurable disease per RECIST version . by radiographic techniques or magnetic resonance imaging
+Patients must have at least  evaluable lesion. Lesions must be evaluated by computed tomography (CT) scan or magnetic resonance imaging (MRI)
+Patients with non-quantifiable monoclonal proteins are eligible provided they meet other criteria for multiple myeloma and they have evaluable or measurable disease by other (radiographic, magnetic resonance imaging [MRI], computed tomography [CT], lytic measurable lesion on x-ray,) means
+Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST . criteria\r\n* Target lesions may be located in a previously irradiated field if there is documented (radiographic) disease progression in that site after the completion of radiation therapy
+Patients with metastatic disease, target lesion must be measurable using computed tomography (CT) or magnetic resonance imaging (MRI)
+Must have disease measurable by RECIST . criteria using either computed tomography (CT) or magnetic resonance imaging (MRI) scan
+Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST v..
+Has measurable disease (or evaluable if not in MTD expansion cohort) via computed tomography (CT) or magnetic resonance imaging (MRI) scans with or without non-measurable tumors (a lesion in a previously irradiated area is eligible to be considered as measurable disease as long as there is objective evidence of progression of that lesion prior to enrollment)
+Subjects must have at least one lesion that is not within a previously radiated field that is evaluable on computerized tomography (CT) or magnetic resonance imaging (MRI) scan per RECIST version .; if the subjects only evaluable disease is within a previously radiated field, it must have demonstrated progression since the time of radiation
+Has evaluable tumor burden (measurable and/or non-measurable tumor lesions) assessed by computed tomography scan or magnetic resonance imaging, based on RECIST version .
+Subjects must have measurable disease by computed tomography (CT) scans or magnetic resonance imaging (MRI) per RECIST . criteria; radiographic tumor assessment must be performed within  days prior to first dose of study drug
+Patients with at least  measurable tumor lesion as assessed by Computed Tomography (CT) Scan or Magnetic Resonance Imaging (MRI) according to RECIST ..
+Patients must have measurable disease, documented by clinical, radiographic or histologic criteria; disease must be bi-dimensionally measurable by computed tomography (CT) or magnetic resonance imaging (MRI)
+At least one lesion (measurable and/or non-measurable) that can be accurately assessed at baseline by computerised tomography (CT) magnetic resonance imaging (MRI) or plain X-ray and is suitable for repeated assessment